Literature DB >> 20460528

A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.

Reshmi Parameswaran1, Markus Müschen, Yong-Mi Kim, John Groffen, Nora Heisterkamp.   

Abstract

B-lineage acute lymphoblastic leukemia (ALL) arises by transformation of a progenitor (pre-B) cell. Cure rates in adults remain low and treatment is complicated by support provided by the microenvironment to the leukemic cells, indicating an urgent need to better understand the factors that promote their survival. B-cell-activating factor (BAFF) and its receptor BAFF-R are important for survival and growth of mature normal and malignant B cells but are not expressed on pre-B cells. Unexpectedly, all cells in the primary Philadelphia chromosome (Ph)-positive and Ph-negative ALL samples tested were positive for high BAFF-R cell surface expression. BAFF-R was fully competent to bind BAFF, and stimulation of the receptor activated both the classic and the noncanonical NF-kappaB pathways. Recombinant BAFF supported survival of the ALL cells in the absence of stroma, and it significantly attenuated the rate of apoptosis caused by exposure to nilotinib, a drug used therapeutically to treat Ph-positive ALLs. Surprisingly, BAFF mRNA and protein were also expressed in the same cells but BAFF was not shed into the medium. Our report is the first showing universal expression of BAFF-R by pre-B ALL cells and opens the possibility of blocking its function as an adjuvant therapeutic strategy. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460528      PMCID: PMC2880197          DOI: 10.1158/0008-5472.CAN-10-0300

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes.

Authors:  J Barker; C M Verfaillie
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

2.  Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease.

Authors:  Thomas Enzler; Giuseppina Bonizzi; Gregg J Silverman; Dennis C Otero; George F Widhopf; Amy Anzelon-Mills; Robert C Rickert; Michael Karin
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

4.  TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.

Authors:  A Hatzoglou; J Roussel; M F Bourgeade; E Rogier; C Madry; J Inoue; O Devergne; A Tsapis
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

Review 5.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

6.  An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.

Authors:  B Schiemann; J L Gommerman; K Vora; T G Cachero; S Shulga-Morskaya; M Dobles; E Frew; M L Scott
Journal:  Science       Date:  2001-08-16       Impact factor: 47.728

7.  Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

Authors:  U Kordes; D Krappmann; V Heissmeyer; W D Ludwig; C Scheidereit
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

8.  Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia.

Authors:  Naveed I Khan; Kenneth F Bradstock; Linda J Bendall
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

9.  CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.

Authors:  J Juarez; A Dela Pena; R Baraz; J Hewson; M Khoo; A Cisterne; S Fricker; N Fujii; K F Bradstock; L J Bendall
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

10.  TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

Authors:  X Z Xia; J Treanor; G Senaldi; S D Khare; T Boone; M Kelley; L E Theill; A Colombero; I Solovyev; F Lee; S McCabe; R Elliott; K Miner; N Hawkins; J Guo; M Stolina; G Yu; J Wang; J Delaney; S Y Meng; W J Boyle; H Hsu
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  33 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

2.  Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Authors:  Stephen A Mihalcik; Renee C Tschumper; Diane F Jelinek
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

3.  CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Authors:  Hong Qin; Zhenyuan Dong; Xiuli Wang; Wesley A Cheng; Feng Wen; Weili Xue; Han Sun; Miriam Walter; Guowei Wei; D Lynne Smith; Xiuhua Sun; Fan Fei; Jianming Xie; Theano I Panagopoulou; Chun-Wei Chen; Joo Y Song; Ibrahim Aldoss; Clarisse Kayembe; Luisa Sarno; Markus Müschen; Giorgio G Inghirami; Stephen J Forman; Larry W Kwak
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

4.  Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

Authors:  Yun Dai; Shuang Chen; Li Wang; Xin-Yan Pei; Lora B Kramer; Paul Dent; Steven Grant
Journal:  Br J Haematol       Date:  2011-03-06       Impact factor: 6.998

5.  Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.

Authors:  Geoffrey L Uy; Yen-Michael S Hsu; Amy P Schmidt; Wendy Stock; Theresa R Fletcher; Kathryn M Trinkaus; Peter Westervelt; John F DiPersio; Daniel C Link
Journal:  Leuk Res       Date:  2015-10-01       Impact factor: 3.156

6.  Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

Authors:  J Wild; B J Schmiedel; A Maurer; S Raab; L Prokop; S Stevanović; D Dörfel; P Schneider; H R Salih
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

7.  mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Authors:  Thanh-Trang T Vo; J Scott Lee; Duc Nguyen; Brandon Lui; William Pandori; Andrew Khaw; Sharmila Mallya; Mengrou Lu; Markus Müschen; Marina Konopleva; David A Fruman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

8.  Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.

Authors:  Rocky Pramanik; Xia Sheng; Brian Ichihara; Nora Heisterkamp; Steven D Mittelman
Journal:  Leuk Res       Date:  2013-01-17       Impact factor: 3.156

9.  Diphtheria Toxin/Human B-Cell Activating Factor Fusion Protein Kills Human Acute Lymphoblastic Leukemia BALL-1 Cells: An Experimental Study.

Authors:  Xin-Pu Gao; Zheng-Min Liu; Yu-Lian Jiao; Bin Cui; Yue-Ting Zhu; Jie Zhang; Lai-Cheng Wang; Yue-Ran Zhao
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

10.  Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.

Authors:  Reshmi Parameswaran; Min Lim; Fei Fei; Hisham Abdel-Azim; Anna Arutyunyan; Isabelle Schiffer; Margaret E McLaughlin; Hermann Gram; Heather Huet; John Groffen; Nora Heisterkamp
Journal:  Mol Cancer Ther       Date:  2014-05-13       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.